Compass Pathways Announces First-Ever Phase 3 Human Psilocybin Trial
Psychedelics have long been heralded for their numerous benefits, with recent studies showing that these substances may be useful in the treatment of various mental health conditions. These benefits have increased interest in these substances, with Compass Pathways PLC (NASDAQ: CMPS) recently announcing that the company plans to begin a phase 3 human trial, which will investigate the effectiveness psilocybin in treating depression this year. This will be the first human trial of this magnitude involving psychedelic therapy globally. Compass Pathways is a mental healthcare company focused on transforming patient experiences in mental healthcare. The company has developed a psilocybin…